Study guide

17.5 Gastrointestinal & Dermatologic Conditions

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

17.5 Gastrointestinal & Dermatologic Conditions

Key Takeaways Explain This Topic AI

Irritant contact dermatitis causes burning and stinging on dry cracked skin, while allergic contact dermatitis is a type IV reaction appearing 24 to 72 hours later with intense pruritus and vesicles in geometric patterns.

Isotretinoin is a potent teratogen requiring two forms of contraception, monthly pregnancy testing, and iPLEDGE enrollment.

Topical and oral retinoids and tetracyclines are contraindicated in pregnancy, leaving topical benzoyl peroxide, azelaic acid, clindamycin, and oral erythromycin or cephalexin as acceptable acne options.

Antiviral therapy for herpes zoster is most effective when started within 72 hours of rash onset, and ophthalmic involvement requires urgent referral.

GERD alarm symptoms such as dysphagia, odynophagia, unintended weight loss, anemia, or gastrointestinal bleeding mandate prompt gastroenterology referral and upper endoscopy rather than escalating empiric acid suppression.

Last updated: September 2026

  • Gastrointestinal Conditions: GERD & Irritable Bowel Syndrome
  • Gastroesophageal Reflux Disease (GERD)

GERD is characterized by retrograde flow of gastric contents into the esophagus causing troublesome symptoms or mucosal damage. The core pathophysiology involves transient lower esophageal sphincter (LES) relaxations.

Symptoms: Heartburn (retrosternal burning pain, pyrosis), acid regurgitation, dysphagia, water brash, globus sensation, and extra-esophageal manifestations (chronic cough, asthma exacerbations, hoarseness, dental enamel erosion).

Lifestyle Interventions: Elevate head of bed by 6 to 8 inches; avoid eating within 2 to 3 hours of reclining; achieve weight reduction; eliminate dietary triggers (chocolate, peppermint, high-fat foods, citrus, tomatoes, caffeine, alcohol); cease tobacco smoking.

Stepwise Pharmacotherapy: Antacids (calcium carbonate) for immediate prn relief; Histamine-2 Receptor Antagonists (H2RAs; Famotidine 20 mg PO daily or BID) for mild/intermittent symptoms; Proton Pump Inhibitors (PPIs; Omeprazole 20 mg daily, Pantoprazole 40 mg daily) taken 30 to 60 minutes prior to the first meal of the day for moderate-to-severe symptoms or erosive esophagitis.

Alarm Symptoms ("Red Flags") Mandating Prompt Gastroenterology Referral & EGD:

New-onset dysphagia (difficulty swallowing) or odynophagia (painful swallowing).

Unexplained weight loss, persistent vomiting, or gastrointestinal bleeding (hematemesis, melena, occult blood).

Unexplained iron deficiency anemia or new symptom onset in individuals aged >50–55 years.

Irritable Bowel Syndrome (IBS)

IBS is a chronic functional disorder of the gut-brain interaction characterized by visceral hypersensitivity, altered gastrointestinal motility, and intestinal dysbiosis.

Rome IV Diagnostic Criteria: Recurrent abdominal pain on average at least 1 day per week in the last 3 months , associated with two or more of the following features:

Related to defecation (pain relieved or aggravated by bowel movements).

Associated with a change in stool frequency (increased or decreased stools).

Associated with a change in stool form / appearance (Bristol Stool Form Scale). (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.)

Bristol Stool Form Scale Subtyping:

IBS-C (Constipation-predominant): >25% bowel movements Bristol types 1–2 (hard, lumpy); <25% types 6–7.

IBS-D (Diarrhea-predominant): >25% bowel movements Bristol types 6–7 (mushy, liquid); <25% types 1–2.

IBS-M (Mixed bowel habits): >25% types 1–2 AND >25% types 6–7.

IBS-U (Unclassified): Insufficient stool abnormality to meet above criteria.

Alarm Features Ruling Out Simple IBS: Nocturnal diarrhea awakening patient from sleep, rectal bleeding, unintended weight loss, fever, onset after age 50, or family history of inflammatory bowel disease (IBD) or colorectal cancer.

Midwifery Management: Comprehensive dietary trial of a low-FODMAP diet (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) with dietitian support; soluble fiber supplementation ( psyllium husk ; avoid insoluble bran which worsens bloating); antispasmodics (hyoscyamine, dicyclomine); osmotic laxatives (polyethylene glycol) for IBS-C; loperamide for IBS-D; low-dose tricyclic antidepressants or SSRIs for visceral pain modulation.

  • Dermatologic Conditions: Dermatitis, Acne & Herpes Zoster
  • Contact Dermatitis: Irritant vs. Allergic

Irritant Contact Dermatitis (ICD): Non-immunologic, localized inflammatory reaction resulting from direct physical or chemical damage to the epidermal barrier (soaps, detergents, alcohol hand sanitizers, wet work). Clinically manifests as dry, chapped, erythematous, cracked skin with prominent burning and stinging sensations rather than itching.

Allergic Contact Dermatitis (ACD): Type IV delayed-type hypersensitivity reaction occurring 24 to 72 hours after cutaneous re-exposure to a sensitized allergen (poison ivy/urushiol, nickel, neomycin, fragrances, rubber additives). Clinically manifests as intense pruritus , erythema, edema, and grouped papules, vesicles, and bullae arranged in sharp, linear, or geometric configurations corresponding to contact points. Diagnosed definitively via epicutaneous patch testing.

Management: Identification and strict avoidance of causal agent; skin barrier restoration with ceramide emollients. Topical corticosteroids: apply medium-to-high potency (Triamcinolone acetonide 0.1%, Clobetasol propionate 0.05%) for body/extremities. Use only low-potency corticosteroids (Hydrocortisone 1% or 2.5%) on the face, groin, axillae, and intertriginous areas to prevent cutaneous atrophy, striae, and telangiectasias. For severe, extensive ACD (>20% body surface area or facial involvement), prescribe an oral prednisone taper over 14 to 21 days (avoid short 6-day Medrol dose packs which trigger severe rebound dermatitis).

Acne Vulgaris & Teratogenic Hazards

Pathophysiology: Follicular hyperkeratinization, sebum overproduction (androgen-driven), Cutibacterium acnes proliferation, and inflammatory cytokine release.

Stepwise Topical & Systemic Therapy:

Mild comedonal/inflammatory: Topical retinoid (Adapalene 0.1%, Tretinoin) plus topical Benzoyl Peroxide (BPO).

Moderate papulopustular: Topical retinoid + BPO + topical antibiotic (Clindamycin 1% combined with BPO to prevent resistance); add oral antibiotic (Doxycycline 50–100 mg BID, limited to a 3- to 4-month course).

Hormonal therapy in women: Combined oral contraceptives (COCs) or Spironolactone (50–200 mg daily; requires concurrent reliable contraception due to feminization risk in male fetuses).

Severe recalcitrant nodulocystic: Oral Isotretinoin (13-cis-retinoic acid).

Isotretinoin Teratogenicity & The iPLEDGE REMS Program:

Isotretinoin is a catastrophic teratogen causing major craniofacial, cardiac, thymic, and central nervous system anomalies in up to 30% to 50% of exposed fetuses, along with severe cognitive deficits in surviving children.

iPLEDGE Requirements for Reproductive-Potential Patients: Mandatory registration in the federal iPLEDGE REMS registry; two negative CLIA-certified pregnancy tests obtained prior to initiating therapy; agreement to use two complementary forms of effective contraception (or practice absolute abstinence) starting 1 month prior to therapy, continuously throughout therapy, and for 1 full month following treatment cessation; monthly negative pregnancy tests confirmed in the portal prior to receiving a strictly capped 30-day medication supply with zero refills.

Herpes Zoster (Shingles)

Etiology: Reactivation of latent Varicella-Zoster Virus (VZV) sequestered in dorsal root or cranial nerve sensory ganglia.

Presentation: Dermatomal prodromal burning pain, paresthesias, and hyperesthesia lasting 2 to 3 days, followed by the eruption of unilateral, grouped, erythematous papules that rapidly evolve into clear vesicles distributed along a single dermatome (does not cross midline) . Most common in thoracic and lumbar dermatomes.

Complications:

Postherpetic Neuralgia (PHN): Severe, debilitating neuropathic pain persisting for >90 days after rash resolution.

Herpes Zoster Ophthalmicus (HZO): Involves the ophthalmic division (V1) of the trigeminal nerve. The presence of vesicles on the tip or side of the nose ( Hutchinson sign ) indicates nasociliary branch involvement and carries a high risk of corneal ulceration, uveitis, and permanent blindness; requires immediate emergency ophthalmology consultation.

Antiviral Pharmacotherapy: Must be initiated within 72 hours of rash onset to accelerate healing, blunt acute neuralgia, and reduce PHN incidence:

Valacyclovir: 1,000 mg PO TID for 7 days (preferred due to superior bioavailability and dosing convenience).

Famciclovir: 500 mg PO TID for 7 days .

Acyclovir: 800 mg PO 5 times daily for 7 days .

Prevention: Recombinant zoster vaccine ( Shingrix ), a 2-dose intramuscular series (at 0 and 2–6 months) for immunocompetent adults aged ≥50 years and immunocompromised adults aged ≥19 years (>90% efficacy in preventing shingles and PHN).